Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists

Cancer Letters

Volumn 120, Issue 1, 1997, Pages 53-63

  McDougal, Andrew ^a   Wilson, Cody ^a   Safe, Stephen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Ah receptor agonist; Antitumorigenicity; Mammary

Indexed keywords

1,3,8 TRICHLORO 6 METHYLDIBENZOFURAN; 6 CYCLOHEXYL 1,3,8 TRICHLORODIBENZOFURAN; 7,12 DIMETHYLBENZ[A]ANTHRACENE; 8 METHYL 1,3,6 TRICHLORODIBENZOFURAN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; BENZOFURAN DERIVATIVE; ETHOXYRESORUFIN DEETHYLASE; LIVER ENZYME; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FEMALE; IMMUNOBLOTTING; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER WEIGHT; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BENZOFURANS; CYTOCHROME P-450 CYP1A1; DNA-BINDING PROTEINS; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ARYL HYDROCARBON; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0030731436     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00299-1     Document Type: Article

References (70)

1. Kelsey J.L., Berkowitz G.S. Breast cancer epidemiology. Cancer Res. 48:1988;5615-5623.
2. Muss H.B. Endocrine therapy for advanced breast cancer - a review. Breast Cancer Res. Treat. 21:1992;15-26.
3. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocrine Rev. 11:1990;221-265.
4. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award Lecture. Cancer Res. 50:1990;4177-4189.
5. Jordan V.C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol. 110:1993;507-517.
6. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma; suggestions for a new method of treatment with illustrative cases. Lancet. 2:1986;104-107.
7. Jordan V.C., Murphy C.S. Endocrine pharmacology of antiestrogens. Endocrine Rev. 11:1990;578-610.
8. Katzenellenbogen B.S., Montano M.M., Le Goff P., Schodin D.J., Kraus W.L., Bhardwaj B., Fujimoto N. Antiestrogens: mechanisms and actions in target cells. J. Steroid Biochem. Mol. Biol. 53:1995;387-393.
9. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the 'pure' antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA. 87:1990;6883-6887.
10. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA. 89:1992;4037-4041.
11. Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 53:1993;3229-3232.
12. Stewart H.J., Forrest A.P., Everington D., McDonald C.C., Dewar J.A., Hawkins R.A., Prescott R.J., George W.D. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br. J. Cancer. 74:1996;297-299.
13. Cook L.S., Weiss N.S., Schwartz S.M., White E., McKnight B., Moore D.E., Daling J.R. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J. Natl. Cancer Inst. 87:1995;1359-1364.
14. Fisher B., Dignam J., Bryant J., Decillis A., Wickerham D.L., Wolmark N., Costantino J., Redmond C., Fisher E.R., Bowman D.M., Deschenes L., Dimitrov N.V., Margolese R.G., Robidoux A., Shibata H., Terz J., Paterson A.H.G., Feldman M.I., Farrar W., Evans J., Lickley H.L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 88:1996;1529-1542.
15. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., Carbone P.P., Demets D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:1992;852-856.
16. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86:1994;1534-1539.
17. Swain S.M. Tamoxifen - the long and short of it. J. Natl. Cancer Inst. 88:1996;1510-1512.
18. Jordan V.C. Tamoxifen and tumorigenicity: a predictable concern. J. Natl. Cancer Inst. 87:1995;623-625.
19. Moon R.C., Mehta R.G. Chemoprevention of mammary cancer by retinoids. Basic Life Sci. 52:1990;213-224.
20. Costa A., Formelli F., Chiesa F., Decensi A., De Palo G., Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 54:1994;2032s-2037s.
21. Kennedy M.J., Prestigiacomo L.J., Tyler G., May W.S., Davidson N.E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res. 52:1992;1278-1283.
22. Safe S. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol. Ther. 67:1995;247-281.
23. Gierthy J.F., Lincoln D.W., Gillespie M.B., Seeger J.I., Martinez H.L., Dickerman H.W., Kumar S.A. Suppression of estrogen-regulated extracellular plasminogen activator activity of MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 47:1987;6198-6203.
24. Gierthy J.F., Lincoln D.W. Inhibition of postconfluent focus production in cultures of MCF-7 breast cancer cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Breast Cancer Res. 12:1988;227-233.
25. Biegel L., Safe S. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 37:1990;725-732.
26. Chaloupka K., Krishnan V., Safe S. Polynuclear aromatic hydrocarbon carcinogens as antiestrogens in MCF-7 human breast cancer cells. Role of the Ah receptor. Carcinogenesis. 13:1992;2223-2239.
27. Krishnan V., Narasimhan T.R., Safe S. Development of gel staining techniques for detecting the secretion of procathepsin D (52-kDa protein) in MCF-7 human breast cancer cells. Anal. Biochem. 204:1992;137-142.
28. Krishnan V., Safe S. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships. Toxicol. Appl. Pharmacol. 120:1993;55-61.
29. Liu H., Wormke M., Safe S., Bjeldanes L.F. Indolo[3,2-b]carbazole: a dietary factor which exhibits both antiestrogenic and estrogenic activity. J. Natl. Cancer Inst. 86:1994;1758-1765.
30. R) human breast cancer cells: a unique aryl hydrocarbon (Ah)-nonresponsive clone. J. Biol. Chem. 269:1994;11751-11759.
31. Wang X., Porter W., Krishnan V., Narasimhan T.R., Safe S. Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. Mol. Cell. Endocrinol. 96:1993;159-166.
32. Zacharewski T., Harris M., Safe S. Evidence for a possible mechanism of action of the 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decrease of nuclear estrogen receptor levels in wild-type and mutant Hepa 1c1c7 cells. Biochem. Pharmacol. 41:1991;1931-1939.
33. Tiwari R.K., Guo L., Bradlow H.L., Telang N.T., Osborne M.P. Selective responsiveness of breast cancer cells to indole-3-carbinol, a chemopreventative agent. J. Natl. Cancer Inst. 86:1994;126-131.
34. Zacharewski T., Harris M., Biegel L., Morrison V., Merchant M., Safe S. 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: evidence for the role of the Ah receptor. Toxicol. Appl. Pharmacol. 13:1992;311-318.
35. Lu Y.-F., Sun G., Wang X., Safe S. Inhibition of prolactin receptor gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 human breast cancer cells. Arch. Biochem. Biophys. 332:1996;35-40.
36. Harper N., Wang X., Liu H., Safe S. Inhibition of estrogen-induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists. Mol. Cell. Endocrinol. 104:1994;47-55.
37. Zacharewski T., Bondy K., McDonell P., Wu Z.F. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17β-estradiol-induced pS2 expression. Cancer Res. 54:1994;2707-2713.
38. Kociba R.J., Keyes D.G., Beger J.E., Carreon R.M., Wade C.E., Dittenber D.A., Kalnins R.P., Frauson L.E., Park C.L., Barnard S.D., Hummel R.A., Humiston C.G. Results of a 2-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicol. Appl. Pharmacol. 46:1978;279-303.
39. Holcomb M., Safe S. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett. 82:1994;43-47.
40. Gierthy J.F., Bennett J.A., Bradley L.M., Cutler D.S. Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 53:1993;3149-3153.
41. Grubbs C.J., Steele V.E., Casebolt T., Juliana M.M., Eto I., Whitaker L.M., Dragnev K.H., Kelloff G.J., Lubet R.L. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res. 15:1995;709-716.
42. Krishnan V., Porter W., Santostefano M., Wang X., Safe S. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol. Cell. Biol. 15:1995;6710-6719.
43. Safe S. MCDF, 6-methyl-1,3,8-trichlorodibenzofuran. Drugs Future. 17:1992;564-565.
44. Astroff B., Zacharewski T., Safe S., Arlotto M.P., Parkinson A., Thomas P., Levin W. 6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities. Mol. Pharmacol. 33:1988;231-236.
45. Harris M., Zacharewski T., Astroff B., Safe S. Partial antagonism of 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated induction of aryl hydrocarbon hydroxylase by 6-methyl-1,3,8-trichlorodibenzofuran: mechanistic studies. Mol. Pharmacol. 35:1989;729-735.
46. Bannister R., Biegel L., Davis D., Astroff B., Safe S. 6-Methyl-1,3,8-trichlorodibenzofuran (MCDF) as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist in C57BL/6 mice. Toxicology. 54:1989;139-150.
47. Yao C., Safe S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced porphyria in genetically inbred mice: partial antagonism and mechanistic studies. Toxicol. Appl. Pharmacol. 100:1989;208-216.
48. Astroff B., Safe S. 6-Substituted-1,3,8-trichlorodibenzofurans as 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonists in the rat: structure-activity relationships. Toxicology. 59:1989;285-296.
49. Astroff B., Safe S. Comparative antiestrogenic activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 6-methyl-1,3,8-trichlorodibenzofuran in the female rat. Toxicol. Appl. Pharmacol. 95:1988;435-443.
50. Astroff B., Safe S. 6-Alkyl-1,3,8-trichlorodibenzofurans as antiestrogens in female Sprague-Dawley rats. Toxicology. 69:1991;187-197.
51. G. Sun, S. Safe, Antiestrogenic activities of alternate substituted polychlorinated dibenzofurans in MCF-7 human breast cancer cells. Cancer Chemother. Pharmacol. 1997, in press.
52. Dickerson R., Howie-Keller L., Safe S. Alkyl polychlorinated dibenzofurans and related compounds as antiestrogens in the female rat uterus: structure-activity studies. Toxicol. Appl. Pharmacol. 135:1995;287-298.
53. Farrell K., Safe L., Safe S. Synthesis and aryl hydrocarbon receptor binding properties of radiolabeled polychlorinated dibenzofuran congeners. Arch. Biochem. Biophys. 259:1987;185-195.
54. Huggins C., Grand L.C., Brillantes F.P. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature. 189:1961;204-207.
55. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
56. Perdew G.H., Abbott B., Stanker L.H. Production and characterization of monoclonal antibodies directed against the Ah receptor. Hybridoma. 14:1995;279-283.
57. Pohl R.J., Fouts J.R. A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem. 107:1980;150-155.
58. Brodie A.M. Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacol. Ther. 60:1993;501-515.
59. Brodie A.M., Marsh D.A., Wu J.T., Brodie H.J. Aromatase inhibitors and their use in controlling oestrogen-dependent processes. J. Steroid Biochem. 11:1979;107-112.
60. Wattenburg L.W., Loub W.D. Inhibition of aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res. 38:1978;1410-1413.
61. Bertazzi P.A., Pesatori A.C., Consonni D., Tironi A., Landi M.T., Zocchetti C. Cancer incidence in a population accidentally exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Epidemiology. 4:1993;398-406.
62. Kojima T., Tanaka T., Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indol-3-carbinol. Cancer Res. 54:1994;1446-1449.
63. Tanaka T., Mori Y., Morishita Y., Hara A., Ohno T., Kojima T., Mori H. Inhibitory effect of sinigrin and indole-3-carbinol in diethylnitrosamine-induced hepatocarcinogenesis in male ACI/N rats. Carcinogenesis. 11:1990;1403-1406.
64. Tanaka T., Kojima T., Morishita Y., Mori H. Inhibitory effects of the natural products indole-3-carbinol and sinigrin during initiation and promotion phases of 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Jpn. J. Cancer Res. 83:1992;835-842.
65. Baron J.A., La Vecchia C., Levi F. The antiestrogenic effect of cigarette smoking in women. Am. J. Obstet. Gynecol. 162:1990;502-514.
66. Lesko S.M., Rosenberg L., Kaufman D.W., Helmrich S.P., Miller D.R., Strom B., Schottenfeld D., Rosenschein N.B., Knapp R.C., Lewis J., Shapiro S. Cigarette smoking and the risk of endometrial cancer. N. Engl. J. Med. 313:1985;593-596.
67. Santostefano M., Safe S. Characterization of the molecular and structural properties of the transformed and nuclear aryl hydrocarbon (Ah) receptor complexes by proteolytic digestion. Chem.-Biol. Interact. 100:1996;221-240.
68. Safe S., Mason G., Sawyer T., Zacharewski T., Harris M., Yao C., Keyes B., Farrell K., Holcomb M., Davis D., Safe L., Piskorska-Pliszczynska J., Leece B., Denomme M.A., Hutzinger O., Thoma H., Chittim B., Madge J. Development and validation of in vitro induction assays for toxic halogenated mixtures. Toxicol. Indust. Health. 5:1989;757-775.
69. Hellmold H., Lamb J.G., Wyss A., Gustafsson J.A., Warner M. Developmental and endocrine regulation of P450 isoforms in rat breast. Mol. Pharmacol. 48:1995;630-638.
70. Jordan V.C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer. 12:1976;419-424.